PMID- 30578169
OWN - NLM
STAT- MEDLINE
DCOM- 20200622
LR  - 20200622
IS  - 1878-0938 (Electronic)
IS  - 1878-0938 (Linking)
VI  - 20
IP  - 10
DP  - 2019 Oct
TI  - Biodegradable-Polymer Versus Polymer-Free Drug-Eluting Stents for the Treatment 
      of Coronary Artery Disease.
PG  - 865-870
LID - S1553-8389(18)30613-4 [pii]
LID - 10.1016/j.carrev.2018.12.010 [doi]
AB  - BACKGROUND/PURPOSE: Biodegradable-polymer (BP) and polymer-free (PF) drug eluting 
      stents (DES) were developed to reduce the risk of delayed arterial healing 
      observed with durable-polymer (DP) platforms. Although trials demonstrate BP-DES 
      and PF-DES are non-inferior to DP-DES, there is limited data directly comparing 
      these technologies. We performed a meta-analysis to assess the efficacy and 
      safety of BP-DES versus PF-DES for the treatment of coronary artery disease. 
      METHODS/MATERIALS: Electronic searches were performed identifying randomized 
      trials comparing BP-DES with PF-DES. Co-primary efficacy endpoints were target 
      vessel revascularization (TVR), target lesion revascularization (TLR) and 
      angiographic in-stent late lumen loss (LLL). Co-secondary safety endpoints were 
      all-cause death, myocardial infarction (MI) and stent thrombosis (ST). RESULTS: 
      Of 208 studies, 5 met inclusion criteria including 1975 patients. At mean 
      follow-up (14 +/- 5 months), BP-DES were associated with significantly reduced 
      rates of TVR (OR 0.58, 95%CI 0.37-0.92, p = 0.02), TLR (4.7% vs 9.5%) (OR 0.48, 
      95%CI 0.31-0.75, p = 0.001) and in-stent LLL (pooled mean difference -0.20 mm, 
      95%CI -0.24 to -0.16, p < 0.001). There was no difference in safety, including 
      all-cause death (OR 1.24, 95%CI 0.68-2.28, p = 0.48), MI (OR 0.92, 95%CI 
      0.54-1.56, p = 0.75) or ST (OR 1.58, 95%CI 0.67-3.73, p = 0.30). CONCLUSIONS: 
      These data suggests that BP-DES are more efficacious when compared with PF-DES 
      for the treatment of CAD.
CI  - Copyright (c) 2018 Elsevier Inc. All rights reserved.
FAU - Nogic, Jason
AU  - Nogic J
AD  - Monash Cardiovascular Research Centre, Monash University and MonashHeart, Monash 
      Health, Melbourne, Victoria, Australia.
FAU - Thein, Paul
AU  - Thein P
AD  - Monash Cardiovascular Research Centre, Monash University and MonashHeart, Monash 
      Health, Melbourne, Victoria, Australia.
FAU - Mirzaee, Sam
AU  - Mirzaee S
AD  - Monash Cardiovascular Research Centre, Monash University and MonashHeart, Monash 
      Health, Melbourne, Victoria, Australia.
FAU - Comella, Andrea
AU  - Comella A
AD  - Monash Cardiovascular Research Centre, Monash University and MonashHeart, Monash 
      Health, Melbourne, Victoria, Australia.
FAU - Soon, Kean
AU  - Soon K
AD  - Department of Cardiology, Eastern Health, Melbourne, Victoria, Australia.
FAU - Cameron, James D
AU  - Cameron JD
AD  - Monash Cardiovascular Research Centre, Monash University and MonashHeart, Monash 
      Health, Melbourne, Victoria, Australia.
FAU - West, Nick E J
AU  - West NEJ
AD  - Department of Interventional Cardiology, Royal Papworth Hospital, Cambridge, UK.
FAU - Brown, Adam J
AU  - Brown AJ
AD  - Monash Cardiovascular Research Centre, Monash University and MonashHeart, Monash 
      Health, Melbourne, Victoria, Australia. Electronic address: ajdbrown@me.com.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20181214
PL  - United States
TA  - Cardiovasc Revasc Med
JT  - Cardiovascular revascularization medicine : including molecular interventions
JID - 101238551
RN  - 0 (Polymers)
SB  - IM
MH  - *Absorbable Implants
MH  - Cause of Death
MH  - Coronary Artery Disease/diagnostic imaging/mortality/physiopathology/*therapy
MH  - Coronary Thrombosis/mortality
MH  - *Drug-Eluting Stents
MH  - Humans
MH  - Myocardial Infarction/mortality
MH  - Percutaneous Coronary Intervention/adverse effects/*instrumentation/mortality
MH  - *Polymers
MH  - Prosthesis Design
MH  - Randomized Controlled Trials as Topic
MH  - Risk Factors
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Biodegradable-polymer stent
OT  - Coronary artery disease
OT  - Drug-eluting stent
OT  - Percutaneous coronary intervention
OT  - Polymer-free stent
EDAT- 2018/12/24 06:00
MHDA- 2020/06/23 06:00
CRDT- 2018/12/23 06:00
PHST- 2018/11/07 00:00 [received]
PHST- 2018/12/07 00:00 [revised]
PHST- 2018/12/11 00:00 [accepted]
PHST- 2018/12/24 06:00 [pubmed]
PHST- 2020/06/23 06:00 [medline]
PHST- 2018/12/23 06:00 [entrez]
AID - S1553-8389(18)30613-4 [pii]
AID - 10.1016/j.carrev.2018.12.010 [doi]
PST - ppublish
SO  - Cardiovasc Revasc Med. 2019 Oct;20(10):865-870. doi: 
      10.1016/j.carrev.2018.12.010. Epub 2018 Dec 14.